Starting children on an insulin pump within 6 months of type 1 diabetes diagnosis is associated with improved outcomes relative to delaying for 2 or 3 years, shows an analysis of data from the DPV registry.
Add-on treatment with the SGLT1 and 2 inhibitor sotagliflozin may reduce cardiovascular risk among patients with type 2 diabetes and chronic kidney disease, suggest findings from the SCORED trial published in The New England Journal of Medicine.
Starting sotagliflozin in people with type 2 diabetes during or shortly after hospitalization for heart failure significantly reduces their risk for further cardiovascular events over the following months, show the results of the SOLOIST-WHF trial.
Geographic remoteness is strongly associated with a reduced likelihood of being prescribed the most recent classes of glucose-lowering medications, find Australian researchers.
Secondary analysis of the VERTIS CV trial supports a significant protective effect of ertugliflozin on risk for heart failure in people with type 2 diabetes, despite the overall neutral outcome of the trial.
Miles Fisher comments on the findings from the EMPEROR-Reduced trial, which demonstrated cardioprotective effects of empagliflozin irrespective of diabetes in patients with heart failure, and discusses whether SGLT2 inhibitors should be incorporated into heart failure treatment guidelines (5:08).
DAPA-CKD lead investigator Hiddo Heerspink discusses the positive outcomes of dapagliflozin treatment in people with kidney disease both with and without type 2 diabetes (8:13).
Lead investigator Milton Packer compares the EMPEROR-Reduced results with those of the DAPA-HF trial, and talks about how SGLT2 inhibitors will impact the treatment of heart failure (6:27).
The VERTIS-CV investigators have presented further kidney outcomes data, supporting the renoprotective effects of the SGLT2 inhibitor medication class.
Phase 3 trials of tirzepatide in type 2 diabetes and obesity
Tirzepatide (formerly known as LY3298176) is a novel glucose-lowering medication that stimulates the receptors for both glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1.
A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.
Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.
Themed collections
Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.
Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.
